General Information of Drug (ID: DMDQO0S)

Drug Name
BMS-753493 Drug Info
Synonyms
Epofolate; Epothilone folate conjugate; BMS-493; BMS-748285 folate conjugate, Bristol-Myers Squibb; Targeted epothilone-folate conjugate (Endocyte technology, cancer), BMS; Targeted epothilone-folate conjugate (Endocyte technology, cancer), Bristol-Myers Squibb
Indication
Disease Entry ICD 11 Status REF
Solid tumour/cancer 2A00-2F9Z Phase 1/2 [1]
Cross-matching ID
PubChem CID
135566069
CAS Number
CAS 958646-17-8
TTD Drug ID
DMDQO0S

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Pyrimethamine DM5X7VY Malaria 1F40-1F45 Approved [3]
Mirvetuximab soravtansine DM5S4LX Ovarian cancer 2C73 Approved [4]
EC20 DMLA1ER Ovarian cancer 2C73 Phase 3 [5]
MK-8109 DM84LO5 Ovarian cancer 2C73 Phase 3 [6]
Farletuzumab DMFLWX1 Non-small-cell lung cancer 2C25.Y Phase 3 [7]
EC-145 DM0KVJC Solid tumour/cancer 2A00-2F9Z Phase 2 [8]
FolateImmune DMB9ADM Renal cell carcinoma 2C90 Phase 2 [9]
Talotrexin DM1AB4L Solid tumour/cancer 2A00-2F9Z Phase 1/2 [10]
EC0489 DM8RD4T Solid tumour/cancer 2A00-2F9Z Phase 1 [11]
IMGN-853 DMR8OG2 Solid tumour/cancer 2A00-2F9Z Phase 1 [12]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Folate receptor alpha (FOLR1) TTVC37M FOLR1_HUMAN Modulator [2]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 2641).
2 A phase I pharmacokinetic and safety analysis of epothilone folate (BMS-753493), a folate receptor targeted chemotherapeutic agent in humans with advanced solid tumors. Invest New Drugs. 2015 Apr;33(2):321-31.
3 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services.
4 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
5 EP patent application no. 2822386, Folate receptor alpha binding ligands.
6 A current review of folate receptor alpha as a potential tumor target in non-small-cell lung cancer. Drug Des Devel Ther. 2015; 9: 4989-4996.
7 Farletuzumab (a monoclonal antibody against folate receptor alpha) in relapsed platinum-sensitive ovarian cancer.Gynecol Oncol.2013 Jun;129(3):452-8.
8 Significance of Folate Receptor alpha and Thymidylate Synthase Protein Expression in Patients with Non-Small Cell Lung Cancer treated with Pemetrexed. J Thorac Oncol. 2013 January; 8(1): 19-30.
9 Responsiveness of the Effective Consumer Scale (EC-17). J Rheumatol. 2009 Sep;36(9):2087-91.
10 Cancer chemotherapy: targeting folic acid synthesis. Cancer Manag Res. 2010; 2: 293-301.
11 National Cancer Institute Drug Dictionary (drug id 638649).
12 Tumor delivery and in vivo processing of disulfide-linked and thioether-linked antibody-maytansinoid conjugates. Bioconjug Chem. 2010 Jan;21(1):84-92.